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ABSTRACT
Between January 1980 and December 1998, 3458 cases of Legionnaires’ disease were reported to the
national surveillance scheme in England and Wales. Of these, 463 (13.4%) were reported as proven by
culture and isolation of Legionella spp., with 96.3% being Legionella pneumophila. Serogroup (Sgp),
monoclonal antibody (mAb) subgrouping and restriction fragment length polymorphism (RFLP)
analysis data were obtained for 321 (69.3%) of these, of which 284 were classified as being unrelated to
any other isolate in the study. Typing data were also available for 117 unrelated environmental isolates
of L. pneumophila obtained from England and Wales, giving a total of 401 unrelated isolates in the study.
Of the clinical isolates, 88.0% were Sgp1, compared with only 42.7% of environmental isolates
(p <0.001); 79.6% of clinical isolates were subgrouped as mAb2+, compared with only 12.8% of
environmental isolates (p <0.001). RFLP typing identified 67 types among the 401 isolates, with clinical
isolates showing significantly less diversity than environmental isolates (index of diversity (IOD) 0.944
vs. 0.958; p <0.05), with three RFLP types (1, 5 and 14) accounting for 40.0% of all clinical isolates.
Combining the phenotypic and genotypic data resulted in 173 distinct phenons, with clinical isolates
showing significantly less diversity than environmental isolates (IOD 0.964 vs. 0.996; p <0.01). Three
phenons accounted for 30% of all clinical isolates. These data strongly suggest that some strains of
L. pneumophila are more likely to cause human infection than would be expected from their distribution
in the environment.
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INTRODUCTION
Legionnaires’ disease (LD) has been investigated
in England and Wales since 1978, and national
surveillance has been in place since 1980. While
serology and urinary antigen detection have been
the diagnostic methods used most widely, culture
and isolation of the organism has always been
considered to be the diagnostic reference stand-
ard. Not only is culture 100% specific, but the
availability of clinical isolates allows their charac-
teristics to be compared, and together with envi-
ronmental isolates, enables epidemiological
typing to be undertaken during outbreak investi-
gations.
The genus Legionella comprises c. 50 species,
almost half of which have been recovered from
clinical samples [1]. However, Legionella pneumo-
phila is the only species that can be regarded as a
significant pathogen. As L. pneumophila is also
found commonly in the environment, both phen-
otypic and genotypic typing methods have been
developed to subdivide this species. Classically,
Legionella isolates have been subdivided into
serogroups on the basis of their reactions with
hyper-immune rabbit antisera. Currently, more
than 60 serogroups are recognised in the genus,
including 15 among L. pneumophila isolates. To
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achieve further phenotypic discrimination,
L. pneumophila serogroup 1 (Sgp1) strains can be
subgrouped using panels of monoclonal antibod-
ies (mAbs), with the international subgrouping
scheme recognising ten mAb subgroups [2].
Over the years, many genotypic typing meth-
ods have been developed for L. pneumophila [3],
of which one was based on analysis of restriction
fragment length polymorphisms (RFLPs) detected
in NciI-digested total genomic DNA [4]. This
method, which has been shown to be robust and
reproducible [3], enabled isolates to be allocated
to defined ‘types’, and thus allowed strain char-
acteristics to be monitored over long periods. This
RFLP method was used routinely for investiga-
tions into all culture-confirmed incidents of Leg-
ionella infection in England and Wales until
January 1999, and was then replaced by the
internationally standardised amplified fragment-
length polymorphism typing method developed
by members of the European Working Group on
Legionella Infections [5]. By the time that the
RFLP method was replaced, 101 RFLP types had
been identified (personal unpublished data).
The purpose of the present study was to review
the large body of typing data generated in the UK
during a 19-year period, and thus to identify the
similarities and differences between clinical and
environmental strains that might illuminate the
epidemiology of LD among residents of England
and Wales.
MATERIALS AND METHODS
Epidemiological data
The National Surveillance Scheme for LD among residents of
England and Wales was established in 1980 by the Public
Health Laboratory Service (now the Health Protection
Agency). Cases that meet the national case definition (i.e., a
relevant pneumonic illness with microbiological evidence of
infection) are reported using a standard reporting form, which
requests details concerning the patient, a clinical history, and
the method of diagnosis of the infection. In addition, infor-
mation concerning possible sources of exposure is requested in
order to determine whether the case might be hospital- or
community-acquired, or travel-associated. Environmental
investigations are normally performed by the public health
staff with responsibility for the area in which the case(s)
occurred. More extensive investigations, involving sampling of
potential sources of infection, are normally associated with
clusters of two or more cases that have a common exposure
history.
All cases of LD in residents of England and Wales that were
reported to the Public Health Laboratory Service were includ-
ed in this study, provided that the diagnosis was confirmed by
isolation of Legionella spp. from a clinical specimen, and that
the reported date of onset of symptoms was between January
1980 and December 1998. In addition, in order to analyse
strains associated with outbreaks of LD, patients linked to an
outbreak where at least one case was proven by isolation were
included. Where available, epidemiological data from these
cases included age, gender, occupation, date of onset, under-
lying disease, outcome, whether the patient was hospitalised
during the incubation period (2–10 days) or spent time away
from home, either in the UK or outside the UK, during the 2
weeks before onset, and other exposure risks such as the use of
whirlpools [6].
Bacteria
All clinical isolates of Legionella spp. from the above patients
were included in the study. Where primary isolation of the
organism was not made in the Respiratory and Systemic
Infection Laboratory (RSIL), isolates were sought from the
originating laboratory, either by routine referral or by specific
request to the laboratory once a notification had been made to
the national surveillance scheme. The isolates were divided
into two groups (‘related’ or ‘unrelated’) according to their
origin. Isolates were considered to be related if they were
isolated, within the same year, from patients with a possible or
confirmed common source of infection. Among isolates that
were related, the first isolate to be received by the RSIL from
each outbreak ⁄ cluster was also included in the group of
unrelated isolates.
To serve as a control group, all environmental isolates of
L. pneumophila submitted to the RSIL from sources in England
and Wales during the 19-year period were considered for
inclusion in the study. To ensure that these were as represen-
tative as possible of the overall population of environmental
isolates not associated with human infection, isolates obtained
from water systems known, or thought, to be associated with
human infection (i.e., most isolates in the collection) were
excluded. Where more than one isolate was obtained from the
same source, only the first isolate for which there was a
complete set of typing results was included.
Isolate characterisation
Isolates were characterised and identified to the species and
serogroup level using standard methods [7]. Isolates of L. pneu-
mophilawere examined by RFLP typing as described previously
[4]. In addition, isolates of L. pneumophila Sgp1 were further
subgrouped by immunofluorescent antibody typing, using
panels of mAbs, into one of the ten international subgroups
[2,8–10]. Only the ‘Dresden Panel’ antibodies were available for
a small number of isolates examined at the end of the study
period, and so differentiation between subgroups Oxford and
OLDA was not possible. These isolates were designated as
Oxford ⁄OLDA subgroup. When an isolate did not fit into any of
the ten defined subgroups, it was designated as ‘other’.
Statistical analysis
Mortality rates, according to whether infections were culture-
proven or not, and proportions of culture-positive cases,
according to source of infection and type distribution, and
whether they were clinical or environmental, were calculated
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and compared using chi-square tests. Diversity was assessed
by calculating Hunter and Gaston’s modification of Simpson’s
index of diversity (IOD) [11,12]. CIs were calculated to convey
the precision of these estimates by using the formula described
originally by Simpson [12]. Diversity was also assessed by
calculating and comparing, using chi-square tests, the propor-
tion of the total isolates represented by the most common three
and ten types, respectively.
RESULTS
Epidemiology
During the study period, 3458 cases of legionel-
losis that met the national criteria were reported
to the surveillance scheme, with 463 (13.4%) of
these reported to have been proven by culture
and isolation of Legionella spp. (Fig. 1). The
percentage of cases proven by culture in a
particular year ranged from 3.3% in 1980 to
22.1% in 1992. During the study period, 187
outbreaks ⁄ clusters were identified, accounting for
843 cases (24.4% of the total). At least one clinical
isolate was available for 54 (28.9%) of these
outbreaks, representing 471 (55.9%) of the out-
break-associated cases (13.6% of the total).
Distribution of the 3458 cases by probable
source of infection was as follows: community-
acquired pneumonia (CAP) and travel-associated
infection acquired in the UK, 50.0%; cases asso-
ciated with travel outside the UK, 43.0%; and
patients whose illness was acquired while in
hospital in the UK (nosocomial), 7.0%.
Clinical isolates
In the vast majority (446 ⁄ 463; 96.3%) of culture-
proven cases, L. pneumophila was the causative
agent, with Legionella bozemanii being the second
most common species (16 cases; 3.5%) (all Sgp1).
Legionella longbeachae (Sgp1) was isolated from
one case (0.2%), and a single dual infection by
L. pneumophila Sgp11 and L. longbeachae Sgp1 was
also reported.
Isolates were submitted for mAb subgrouping
and RFLP analysis from 321 (69.3%) of the 446
culture-proven L. pneumophila cases. These repre-
sented 16.7–86.4% of the isolates obtained in each
year (Fig. 1). The distribution of cases according
to probable source of infection was: travel outside
the UK, 44.9%; CAP ⁄ travel in the UK, 42.1%; and
nosocomially acquired cases, 13.1%. Thus, com-
pared to the overall series, nosocomial cases were
over-represented (p <0.01) and CAP ⁄ travel cases
were under-represented (p 0.05) in the culture-
proven series.
Comparison of unrelated isolates
Of the 321 clinical isolates for which typing data
were available, 284 were classified as being
unrelated to any other isolate in the study (travel
outside UK, 139; CAP ⁄ travel in the UK, 114;
nosocomially acquired, 31). Typing data were also
available for 117 unrelated environmental isolates
of L. pneumophila obtained from samples collected
in England or Wales, giving a total of 401
unrelated isolates in the study.
The Sgp and, where appropriate, mAb sub-
group of the unrelated isolates are shown in
Table 1. Overall, 88.0% of clinical isolates be-
longed to Sgp1, compared with only 42.7% of
environmental isolates (p <0.001). Similarly,
79.6% of clinical isolates belonged to the so-called
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Fig. 1. Culture-confirmed cases of
Legionnaires’ disease reported to
the national surveillance scheme
for England and Wales (1980–1998),
showing the number included in
this study.
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‘virulent’ L. pneumophila Sgp1 subgroup (vari-
ously called the Pontiac subgroup [13], the
mAb2+ subgroup [14] or the mAb3 ⁄ 1 subgroup
[10]), compared with only 12.8% of environmen-
tal isolates (p <0.001).
Sixty-seven of the 101 RFLP types recognised
were identified among 399 of 401 unrelated
isolates; two clinical isolates failed to digest with
NciI and were therefore classified as untypeable
[4]. Among the 284 unrelated clinical isolates, 49
types were identified (scoring untypeable as a
distinct type), 29 of which were represented by
single isolates (IOD 0.944; 95% CI 0.939–0.949).
Among the 117 unrelated environmental iso-
lates, 43 types were detected, of which 26 were
represented by single isolates (IOD 0.958; 95%
CI 0.952–0.964). Although these IODs were sim-
ilar, the difference was statistically significant
(p <0.05).
Table 2 shows the RFLP types for the clinical
(subdivided into infections acquired outside the
UK and infections acquired in the UK) and
environmental isolates. Among unrelated clinical
isolates, three RFLP types (types 1, 5 and 14)
accounted for 40.0% of the total, with the ten most
frequent RFLP types accounting for 76.4% of
isolates. In contrast, among the unrelated envi-
ronmental isolates, the three most frequent types
(1, 15 and 26) accounted for only 28.2% (p 0.025),
and the ten most frequent types accounted for
only 62.4% (p 0.01) of isolates. Overall, the dis-
tribution of types differed significantly between
clinical and environmental isolates (p <0.001),
with clinical isolates again showing less diversity.
The main differences were caused by a higher
proportion of clinical isolates belonging to types
5, 14, 10 and 2.
Combining the phenotypic (Sgp ⁄mAb sub-
group) and RFLP data resulted in 173 distinct
Table 1. Distribution of 284 unrelated clinical isolates and
117 unrelated environmental isolates according to pheno-
type (subgroup and ⁄ or serogroup)
Serogroup
(Sgp) mAb subgroup
Clinical
isolates,
no. (%)
Environmental
isolates,
no. (%)
L. pneumophila
Sgp 1 Philadelphiaa 69 (24.3) 7 (6.0)
Allentowna 25 (8.8) 3 (2.6)
Benidorma 80 (28.2) 3 (2.6)
Knoxvillea 33 (11.6) 1 (0.9)
Francea 19 (6.7) 1 (0.9)
(mAb2+) 226 (79.6) 15 (12.8)
OLDA 5 (1.8) 7 (6.0)
Oxford 7 (2.5) 6 (5.1)
Heysham 2 (0.7) 1 (0.9)
Camperdown 0 1 (0.9)
Bellingham 8 (2.8) 14 (12.0)
OLDA ⁄Oxford 1 (0.4) 2 (1.7)
Other 1 (0.4) 4 (3.4)
Total Sgp1 250 (88.0) 50 (42.7)
Sgp2 1 (0.4) 5 (4.3)
Sgp3 8 (2.8) 14 (12.0)
Sgp4 2 (0.7) 0
Sgp5 3 (1.1) 9 (7.7)
Sgp6 6 (2.1) 14 (12.0)
Sgp7 0 3 (2.6)
Sgp8 7 (2.5) 5 (4.3)
Sgp9 0 3 (2.6)
Sgp10 5 (1.8) 3 (2.6)
Sgp11 1 (0.4) 0
Sgp12 1 (0.4) 3 (2.6)
Sgp13 0 0
Sgp14 0 3 (2.6)
Sgp15 0 0
Sgp16 0 5 (4.3)
Totals 284 (100.0) 117 (100.0)
aThese monoclonal antibody (mAb) subgroups comprise the so-called ‘mAb2+’,
‘Pontiac’ or ‘virulent’ subgroup of L. pneumophila serogroup 1.
Table 2. Distribution of 284 unrelated clinical isolates (145
associated with infection acquired in the UK, 139 associ-
ated with infection acquired outside the UK) and 117
unrelated UK environmental isolates, grouped according
to restriction fragment-length polymorphism (RFLP) type
RFLP type
Clinical isolates
Travel (out-
side UK) UK All
Environ-
mental
isolates
n % n % n % n %
1 19 13.7 20 14.4 39 13.7 12 10.3
5 7 5.0 30 21.6 37 13.0 9 7.7
14 28 20.1 10 7.2 38 13.3 0
26 9 6.5 17 12.2 26 9.1 10 8.5
15 9 6.5 8 5.8 17 6.0 11 9.4
10 5 3.6 17 12.2 22 7.7 1 0.9
2 8 5.8 5 3.6 13 4.6 1 0.9
11 5 3.6 5 3.6 10 3.5 4 3.4
28 2 1.4 3 2.2 5 1.8 6 5.1
25 1 0.7 7 5.0 8 2.8 1 0.9
27 0 4 2.9 4 1.4 5 4.3
34 1 0.7 1 0.7 2 0.7 7 6.0
7 2 1.4 0 2 0.7 5 4.3
24 4 2.9 3 2.2 7 2.5 0
29 4 2.9 0 4 1.4 3 2.6
42 1 0.7 1 0.7 2 0.7 4 3.4
19 2 1.4 1 0.7 3 1.1 2 1.7
23 4 2.9 0 4 1.4 1 0.9
37 1 0.7 1 0.7 2 0.7 3 2.6
13 0 0 0 4 3.4
31 1 0.7 0 1 0.4 2 1.7
32 1 0.7 0 1 0.4 2 1.7
62 0 2 1.4 2 0.7 1 0.9
63 2 1.4 1 0.7 3 1.1 0
71 1 0.7 2 1.4 3 1.1 0
4 1 0.7 0 1 0.4 1 0.9
16 1 0.7 0 1 0.4 1 0.9
40 0 0 0 2 1.7
50 0 1 0.7 1 0.4 1 0.9
60 2 1.4 0 2 0.7 0
61 1 0.7 0 1 0.4 1 0.9
87 2 1.4 0 2 0.7 0
89 1 0.7 1 0.7 2 0.7 0
Un 0 2 1.4 2 0.7 0
Other
34 typesa
14 10.1 3 2.1 17 6.0 17 14.5
aOnly those RFLP types represented by two or more isolates are shown
individually.
Un, untypeable (failed to digest with NciI) and considered to be a separate type for
purposes of analysis.
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phenons: 110 for the 284 unrelated clinical isolates
(IOD 0.964; 95% CI 0.959–0.968) and 91 for the
117 unrelated environmental isolates (IOD 0.995;
95% CI 0.994–0.996). The IOD for the clinical
isolates was significantly lower than that for the
environmental isolates (p <0.01).
Among clinical isolates, the three most com-
mon phenons accounted for >30% of all unrelated
isolates (mAb Benidorm RFLP 14, 13.0%; mAb
Philadelphia RFLP 1, 9.5%; mAb Philadelphia
RFLP 5, 7.7%), while the five most common
phenons among the environmental isolates
(Sgp3 RFLP 34, 3.4%; mAb Oxford RFLP 1,
2.6%; mAb OLDA RFLP 1, 2.6%; mAb Philadel-
phia RFLP 5, 2.6%; Sgp3 RFLP 28, 2.6%) only
accounted for 13.7% of unrelated isolates
(p <0.01).
Comparison of unrelated clinical isolates by
origin of infection
The IOD for clinical isolates from infections
acquired outside the UK was significantly higher
(IOD 0.926; 95% CI 0.914–0.937) than that for
isolates obtained from infections acquired within
the UK (IOD 0.902; 95% CI 0.892–0.912; p <0.05).
Although the proportion of isolates represented
by the most common three types was similar for
the two groups (37.25% for those acquired
outside the UK compared with 43.2% for those
acquired within the UK; p 0.31), the proportion
of isolates belonging to the most common ten
types was significantly different (64.1% for those
acquired outside the UK compared with 87.8%
for those acquired within the UK; p <0.01).
Overall, the distribution of RFLP types was
significantly different (p <0.001) between the
two groups, with RFLP type 14 being, by far,
the most common type in infections acquired
outside the UK, and RFLP types 5, 26 and 10
being most common for infections acquired
within the UK (Table 2).
RFLP types associated with outbreaks of LD
Eighteen RFLP types were identified among the
54 outbreaks of LD during the study period for
which isolates were available, with RFLP types 5
(13 ⁄ 54), 14 (8 ⁄ 54) and 1 (6 ⁄ 54) being most com-
mon. All other RFLP types caused five or fewer
outbreaks. Assuming that each outbreak is caused
by a single strain, RFLP type 5 caused 44.6%
(186 ⁄ 417), RFLP type 25 caused 16.3% (68 ⁄ 417)
and RFLP type 14 caused 10.8% (45 ⁄ 417) of all
outbreak-associated cases. Other RFLP types
caused £6% of cases each.
DISCUSSION
Legionellae have been isolated from a diverse
range of man-made habitats, including air-condi-
tioning systems, potable water supplies, orna-
mental fountains, and plumbing fixtures and
fittings in hospitals, shops and homes, where
they comprise part of the normal consortium of
biofilm bacteria [1]. It is these environments that
are the source of almost all cases of LD, with
infection being acquired primarily by inhalation
of aerosols containing viable organisms or, par-
ticularly in the case of immunocompromised
patients, by aspiration of bacteria in water.
Although LD is, overall, a relatively uncommon
form of pneumonia, it is much more significant in
the context of severe pneumonia, probably being
the second commonest form, accounting for 14–
37% of all cases [14]. As LD is essentially a
preventable illness, which manifests frequently as
explosive point source outbreaks [15], both med-
ical and public opinion agree that attempts should
be made to control and prevent such infections.
Eradication of legionellae from man-made
environments has not proved to be possible, with
the evidence suggesting that, once colonised,
water distribution systems, particularly those in
large, complex buildings, retain a relatively con-
stant population of legionellae for many years
[16]. Therefore, strategies for the prevention of LD
focus on keeping the numbers of organisms in
man-made environments to a minimum; hot
water is kept hot, cold water is kept cold, build-
ups of nutrients and biofilm mass are reduced,
and aerosol generation is minimised or, where
unavoidable, is contained. Considerable effort
goes into the implementation of these control
measures and, in most countries, this is under-
pinned by legislation to ensure compliance. How-
ever, despite these efforts, the number of reported
cases of LD continues to rise across Europe, and
outbreaks of major public health significance
continue to occur [15].
The study reported here is the largest to date in
which clinical and environmental isolates ob-
tained over a long period have been compared
systematically. The results were obtained using
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two well-characterised typing methods, namely
mAb subgrouping and RFLP analysis. Both meth-
ods have been shown to be highly reproducible,
both within and among laboratories [3]. A large
number of unrelated clinical isolates obtained
from LD patients who acquired their infections
within the UK or while travelling abroad were
examined, and these were compared with a
representative panel of L. pneumophila environ-
mental isolates, obtained from sources in the UK,
which were not associated with cases of LD.
Almost all (96%) clinical isolates were L. pneu-
mophila, with the vast majority (88%) of these
being Sgp1 and mAb2+ (79%). In contrast, while
Sgp1 was still the most frequent serogroup among
the environmental L. pneumophila isolates, it
accounted for a much smaller percentage (43%),
with only a minority (13%) of isolates being
mAb2. These data confirm and extend earlier
work [17] showing that L. pneumophila Sgp1
strains, particularly of the mAb2+ subgroup, are
much more likely to cause human infection than
are other Sgps and subgroups. This observation
initially raised the possibility that the character-
isation of the mAb2 status of L. pneumophila
strains in a particular environment could be used
as part of the overall risk-assessment process,
with a system containing L. pneumophila mAb2–
strains being considered to be of lower risk than a
system containing mAb2+ strains. However,
recent studies have shown that, while the geno-
type of strains in a particular environment
remained constant, this was not always the case
for the mAb2 phenotype [18]. Thus, while the
presence of a L. pneumophila Sgp 1 mAb2+ strain
in a building would clearly be a cause for
immediate concern and action, the presence of
only mAb2– strains could not, conversely, be
considered as reassuring, at least not for the
longer term. Clearly, genotypic markers of viru-
lence are needed for the long-term monitoring of
legionellae in the environment.
The possibility that clinical isolates might be a
genotypically-restricted subset of all L. pneumo-
phila isolates was first investigated by Selander
et al. [19]. These authors used multilocus enzyme
electrophoresis typing to investigate isolates of
L. pneumophila. The mean genetic diversity was
found to be essentially the same for the clinical
isolates as for the entire population, and it was
concluded that there was no evidence that clinical
isolates were less variable than those from the
environment. This view has been supported by
the analysis of partial DNA sequence data
obtained from five genes [20]. No specific viru-
lence-associated lineages were identified, and it
was concluded that clinical and environmental
isolates could not be distinguished on the basis of
DNA sequence analysis of the five genes ana-
lysed.
In contrast to the above findings, the present
study showed clear differences between the pop-
ulations of clinical and environmental isolates,
with clinical isolates showing less diversity than
environmental isolates, suggesting that the former
are a subset of the latter. Review of the data show
that the difference is caused primarily by the
higher proportions of just a few RFLP types (5, 14,
10 and 2) among the clinical isolates, compared
with the more even distribution of RFLP types
among environmental isolates. This reduced div-
ersity and skewed distribution of RFLP types
remained when the analysis was reassessed using
only clinical and environmental isolates from the
UK. Furthermore, two of these RFLP types (5 and
14) appear to be major causes of outbreaks,
accounting, between them, for more than half of
all evaluable outbreak-associated cases. These
data suggest strongly that some strains are more
likely to cause disease than would be expected
from their relative frequency in the environment.
There are several possible explanations for the
apparent difference between the present data and
those reported by earlier studies. First, the num-
ber of unrelated isolates examined in this study
was substantially higher than in previous studies
(284 clinical, 117 environmental (this study); 99
clinical, 71 environmental [19]; 149 clinical, 28
environmental [20]). If, as seems probable, differ-
ences in strain virulence are quantitative rather
than qualitative, large datasets will be needed to
identify any subtle differences. Second, the var-
ious studies might be measuring different factors.
The previous studies sought to identify differ-
ences between clinical and environmental strains
by comparing their overall genetic diversity,
either inferred (by multilocus enzyme electro-
phoresis), or measured directly (by DNA sequen-
cing). However, the RFLP method used here
simply allocates isolates to their respective ‘type’,
irrespective of the genetic differences among
these types. By definition, isolates of different
RFLP types will be genetically distinct, but the
differences might be very small or very great.
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A small genetic difference, giving rise to a
significant change in virulence, might be detected
by chance when using RFLP typing, but might not
be detected by a method assessing overall genetic
content. A third possibility is that the discrepant
findings reflect differences in the geographical
distribution of the L. pneumophila strains exam-
ined in each study. Some evidence of this was
found, as the clinical isolates from UK-acquired
cases of LD were less diverse than those seen
from cases of LD acquired outside the UK
(although they were still significantly less diverse
than the UK environmental isolates). Unfortu-
nately, this possibility cannot be properly asses-
sed, as no direct comparison can be made
between the present study and the studies cited
above; each used a different methodology and
there were very few isolates in common.
In conclusion, this is the first study to identify
statistically significant differences in the distribu-
tion of genotypes among clinical and environ-
mental strains of L. pneumophila. This does not
necessarily correspond to a direct association
between genotype and virulence, but these obser-
vations, if confirmed, might allow the develop-
ment of rational risk assessments that take account
of both the quantity and the genotype of organ-
isms present in a water system. Although of major
public health significance, LD is rare, and it is only
by pooling data that the scientific community will
be able to obtain sufficient data to rigorously
investigate this disease. With the recent descrip-
tion of an internationally standardised DNA
sequence-based typing scheme, together with
associated databases [21], it is hoped that future
studies will be directly comparable and that large
international datasets will be established.
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